Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NIPEC-OXA in Peritoneal Metastases From Colorectal Cancer
NCT05056389Phase 1Unknown
- Sponsor
- Oslo University Hospital
- Start
- Sep 2021
- Primary completion
- Mar 2023
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of oxaliplatin in Peritoneal metastases and colorectal cancer (CRC), sponsored by Oslo University Hospital. Primary endpoints: Number of Participants with Adverse Events after Intraperitoneal Chemotherapy Administration at 3 months and Number of Participants with Surgical Complications after CRS, HIPEC and NIPEC-OXA at 3 months. Status: unknown.
02
Drugs
oxaliplatin
03
Conditions
Peritoneal metastasescolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05056389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05056389.